13,139 resources
Start Prev Rows 4800 - 5000 Next
Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Auth | Source(s) |
---|---|---|---|---|---|---|---|---|---|
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.343 | Fulvestrant_therapy | active | 2024-07 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.344 | PTEN_gene | active | 2024-07 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.345 | PTEN_geneinterpretation | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.346 | PIK3CA_gene | active | 2024-07 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.347 | PI3KCA_geneinterpretation | active | 2024-07 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.348 | AKTI_gene | active | 2024-07 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.349 | AKTI_geneinterpretation | active | 2024-07 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.350 | Progesterone_receptor_gene | active | 2024-07 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.351 | Progesterone_receptor_geneinterpretation | active | 2024-07 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.352 | Estrogen_receptor_gene | active | 2024-07 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.353 | Estrogen_receptor_geneinterpretation | active | 2024-07 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.354 | Progesterone_receptor_labtest | active | 2024-07 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.355 | Progesterone_receptor_labinterpretation | active | 2024-07 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.356 | Estrogen_receptor_labtest | active | 2024-07 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.357 | Estrogen_receptor_labinterpretation | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.358 | NSCLC M0 Stage | active | 2024-07 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.359 | HER2_IHC_test_Gene | active | 2024-08 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.360 | HER2_IHC_test_Lab | active | 2024-08 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.361 | HER2_Fish_test | active | 2024-08 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.362 | HER2_IHC_Negative | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.363 | Trodelvy | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.364 | Chemotherapy_breast_cancer | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.365 | Cyclin_dependent_kinase | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.366 | Taxane_Trodelvy | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.367 | Endocrine_therapy | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.368 | HER2_Fish_test_Negative | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.369 | HER2_IHC_Equivocal | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.370 | HER2 Positive_PM_results | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.371 | HER2 test_Lab | active | 2024-08 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.372 | HER2 test_gene | active | 2024-08 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.374 | Thyroid Cancer Diagnosis | active | 2024-08 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.375 | Metastatic_Thyroid_Stage Group | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.376 | RET mutation_Molecular Variants | active | 2024-08 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.377 | RET Gene mutation | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.378 | Locally_Advanced_Localized_Thyroid_Cancer_Stage Group | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.379 | Thyroid cancer M1_Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.380 | Thyroid_cancer_M0_Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.381 | Thyroid_cancer_T_Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.382 | Thyroid_cancer_T1_T2_T3_Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.383 | Thyroid_cancer_T4_Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.384 | Thyroid_cancer_N1b_Stage&Above | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.385 | Thyroid_cancer_N_Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.386 | Medullary_thyroid_histology | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.387 | RET test_Thyroid_cancer (HGNC) | active | 2024-08 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.388 | RET Positive | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.389 | NSCLC N3 Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.390 | CRC Cancer Diagnosis ICD9 | active | 2024-08 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.391 | CRC Cancer Diagnosis ICD10 | active | 2024-08 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.392 | CRC Cancer Diagnosis ICD9/ICD10 | active | 2024-08 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.393 | Metastatic_CRC_Cancer_Stage Group | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.394 | Locally_Advanced_Localized_CRC_Stage Group | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.395 | CRC cancer M Stage (metastatic) | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.396 | CRC Cancer T Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.397 | CRC Cancer N Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.398 | KRAS_gene | active | 2024-08 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.399 | KRAS_negative | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.40 | Locoregional Breast Cancer | active | 2023-10 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.400 | Fluoropyrimidine_CRC | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.401 | Oxaliplatin | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.402 | Irinotecan_based_therapy | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.403 | anti_VEGF_therapy_CRC | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.404 | anti_EGFR_therapy_CRC | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.405 | fruquitinib | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.406 | Locally_Advanced_CRC_Stage Group | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.407 | Localized_CRC_Stage Group | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.408 | CRC cancer M0_Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.409 | CRC_Cancer_T1_Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.410 | CRC_Cancer_T2_Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.411 | CRC_Cancer_T3_Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.412 | CRC_Cancer_T4_Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.413 | CRC Cancer N1 Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.414 | CRC Cancer N2 Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.415 | CRC Cancer N2b Stage | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.416 | KRAS_G12C_MV | active | 2024-08 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.417 | KRAS_G12C_PM | active | 2024-08 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.418 | KRAS_positive | active | 2024-08 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.419 | Adagrasib | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.42 | Breast Cancer | active | 2023-10 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.420 | cetuximab_therapy | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.421 | Tamoxifen_therapy | active | 2024-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.423 | Endometrial Cancer Diagnosis ICD 10 | active | 2024-09 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.425 | Endometrial Cancer Diagnosis ICD9CM | active | 2024-09 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.426 | Endometrial Cancer Diagnosis | active | 2024-09 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.428 | Localized_Endometerial_Stage Group SNOMED | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.429 | Localized_Endometerial_Stage Group NCIM | active | 2024-09 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.431 | Endometrial_Sarcoma_Tumor_Histology_exc | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.432 | Endometrial cancer M Stage (metastatic) | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.433 | Endometrial_M0_Stage | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.436 | Prior_therapy_Endometrial | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.437 | Paclitaxel_therapy | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.441 | Carboplatin_therapy | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.442 | Durvalumab_therapy | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.444 | MMR_Gene_Lab_LOINC | active | 2024-09 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.447 | MMR_Gene_HGNC | active | 2024-09 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.449 | Endometrial_ Cancer N Stage | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.451 | Endometrial_N0_Stage | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.453 | Endometrial_N1_N2_Stage | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.455 | Endometrial_T1_T3_Stage | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.456 | Endometrial_T3_Stage | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.458 | Endometrial_T4_Stage | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.459 | Endometrial Cancer T Stage | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.46 | Endometrial Cancer ICD10 | active | 2023-11 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.460 | Localized_Endometerial_Stage Group_SNOMED/NCIM | active | 2024-09 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.461 | Metastatic Sites All CRC | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.462 | Metastatic Sites All CRC ICD 10 | active | 2024-09 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.463 | Metastatic Sites All CRC ICD 9 | active | 2024-09 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.464 | Metastatic Sites All CRC (grouped, SNOMEDCT/ICD9/ICD10) | active | 2024-09 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.465 | NTRK Repotrectinib Molecular Variants | active | 2024-09 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.466 | NTRK_Gene_rearrangment | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.467 | Prior_Systemic_therapy_Repotrectinib | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.468 | NTRK_Positive | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.469 | NTRK_test_gene | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.47 | Systemic treatment for endometrial cancer | active | 2023-11 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.470 | Tamoxifen_Trodelvy | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.471 | Toremifene_trodelvy | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.472 | Fulvestrant_Trodelvy | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.473 | Elacestrant | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.474 | Anastrozole_Trodelvy | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.475 | Leuprolide_Trodelvy | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.476 | Abemaciclib | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.477 | Palbociclib | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.478 | Ribociclib | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.479 | Carboplatin_Trodelvy | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.48 | Endometrial Cancers | active | 2023-11 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.480 | Cisplatin_Trodelvy | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.481 | Cyclophosphamide | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.482 | Methotrexate | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.483 | Gemcitabine | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.484 | Capecitabine | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.485 | Eribulin | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.486 | Doxorubicin | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.487 | Vinorelbine | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.488 | Epirubicin | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.489 | Ixabepilone | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.490 | Olaparib | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.491 | Talazoparib | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.492 | Entrectinib | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.493 | larotrectinib | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.494 | Alpelisib | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.495 | Capivasertib | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.496 | Pembrolizumab | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.497 | Dostarlimab | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.498 | Selpercatinib | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.499 | Everolimus | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.500 | Trastuzumab_deruxtecan | active | 2024-09 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.501 | Test 23 | active | 2024-09 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.502 | All Metastatic sites Endometrial SNOMED | active | 2024-09 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.503 | All Metastatic sites Endometrial ICD9 | active | 2024-09 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.504 | All Metastatic sites Endometrial ICD10 | active | 2024-09 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.505 | All Metastatic sites Endometrial | active | 2024-09 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.506 | Create CRC_Cancer_T4a_Stage | active | 2024-10 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.507 | Create CRC_Cancer_T4b_Stage | active | 2024-10 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.508 | High Emetogenic Risk Chemotherapy | active | 2025-04 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.510 | InactiveFollowup | active | 2025-05 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.53 | MMR Gene Testing | active | 2023-11 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.54 | MSI High | active | 2023-11 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.55 | MSI High | active | 2024-01 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.6 | Orserdu | active | 2023-08 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.61 | Stage IIB or lower and limited | active | 2023-11 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.62 | Stage III or higher | active | 2023-11 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.63 | Stage III or higher | active | 2023-11 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.64 | Stage III or higher | active | 2023-11 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.65 | Staging Unknown | active | 2023-11 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.66 | Staging Unknown | active | 2023-11 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.67 | Staging Unknown | active | 2023-11 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.68 | Jemperli | active | 2023-11 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.69 | Uterine Sarcoma | active | 2023-11 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.7 | Her2 Test For Orserdu | active | 2023-09 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.70 | Tumor Histology | active | 2023-11 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.71 | Platinum based therapy | active | 2023-11 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.72 | Prior Therapies for Tucatinib | active | 2023-12 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.73 | Tucatinib | active | 2023-12 | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.74 | Colorectal Cancer ICD10 | active | 2023-12 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.75 | Colorectal Cancer ICD9 | active | 2023-12 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.76 | Colorectal Cancer ICD9 and ICD10 | active | 2023-12 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.78 | Advanced or Unresectable Colorectal Cancer Staging | active | 2023-12 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.79 | 0 to IIIB Colorectal Cancer Staging | active | 2023-12 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.80 | Colorectal Cancer M1 Stage | active | 2023-12 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.81 | RAS Genes | active | 2023-12 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.82 | RAS Gene Interpretation Negative LOINC | active | 2023-12 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.83 | RAS Gene Interpretation Negative SNOMED | active | 2023-12 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.84 | RAS Gene Interpretation Negative NCM | active | 2023-12 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.85 | RAS Gene Negative | active | 2023-12 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.86 | RAS Gene Interpretation Positive SNOMED | active | 2023-12 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.87 | RAS Gene Interpretation Positive LOINC | active | 2023-12 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.88 | RAS Gene Positive | active | 2023-12 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.89 | Her2 Testing | active | 2023-12 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.90 | Patient Reason | active | 2023-12 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.91 | MSI High NCI | active | 2024-01 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.92 | MSI Low SNOMED | active | 2024-01 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.93 | MSI Low LOINC | active | 2024-01 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.94 | MSI Low NCI | active | 2024-01 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.95 | MSI Low | active | 2024-01 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.96 | MMR Deficient NCI | active | 2024-01 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.97 | MMR Proficient SNOMED | active | 2024-01 | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.98 | MMR Proficient LOINC | active | 2024-01 | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.99 | MMR Proficient NCI | active | 2024-01 | hl7 | ncit | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1262.3 | ICD9 Codes for HIV Diagnosis | active | 2023-10 | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1264.1 | Inpatient Pneumonia Diagnosis | active | 2023-12 | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1264.11 | Chest Imaging for Pneumonia, HCPCS | active | 2023-11 | hl7 | cms |